Please login to the form below

Not currently logged in
Email:
Password:

sanofi dealt FDA Acomplia blow

US regulator declines to approve great white hope of French firm's pipeline

French firm sanofi-aventis suffered a setback after the US Food and Drug Administration (FDA) declined to approve its most promising new product, weight loss drug Acomplia (rimonabant).

sanofi had been hoping to market the potential blockbuster as a treatment for both obesity and smoking, with forecasted annual sales of $3bn. The company said it had received a so-called `approvable' letter for the drug as a weight loss treatment, and a `not approvable' letter for use as a smoking cessation drug.

The 'not approvable' letter effectively ends sanofi's chances of entering the lucrative smoking cessation market with Acomplia.

The drug has created much excitement as it uses a new mechanism for inducing weight loss, blocking receptors in the brain and in fat cells that regulate appetite.

The firm said in a statement that it ìwill continue to work in close collaboration with the FDAî.

Analysts at Dresdner Kleinwort Wasserstein maintained their `hold' rating on sanofi-aventis and said they expected the final FDA approval for Acomplia to be delayed until 2007, adding that if the regulator seeks more data, it could be delayed even further.

In a study published last week in the Journal of the American Medical Association, researchers found that after one year, 48.6 per cent of the people taking the higher dose of the drug, 20mg, had lost 5 per cent or more of their weight, compared with 20 per cent of those taking placebo.

Those who took the drug for a second year managed to keep the weight off, while patients who switched to placebo after taking rimonabant regained some weight.

The study also found that participants showed higher rates of psychiatric side effects such as anxiety and depression.

30th September 2008

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Oncosec

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...

Latest intelligence

Live webinar:
The power of a good story: Turn your insights into effective storytelling with data visualisation...
clinical research org
The important role of CROs in shaping the future of clinical research across Europe
Looking at the impact of COVID-19 on clinical research activities...
What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...

Infographics